DUR 928

Drug Profile

DUR 928

Alternative Names: DUR928; DV-928

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator DURECT Corporation
  • Class Small molecules
  • Mechanism of Action Inflammation mediator modulators; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute kidney injury; Fatty liver; Non-alcoholic steatohepatitis; Psoriasis
  • Preclinical Liver disorders; Stroke

Most Recent Events

  • 30 Nov 2016 DURECT corporation completes a phase I trial in Non-alcoholic steatohepatitis in Australia (PO) (ACTRN12615001355561)
  • 23 Nov 2016 DURECT Corporation completes a phase I trial in Psoriasis in Australia (IV) (ACTRN12616001077459)
  • 13 Sep 2016 DURECT Corporation completes a phase I trial in Healthy volunteers in Australia (IV) (ACTRN12616000856415p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top